Knights of Columbus Asset Advisors LLC Has $1.35 Million Position in ARS Pharmaceuticals, Inc. $SPRY

Knights of Columbus Asset Advisors LLC boosted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 97.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 134,476 shares of the company’s stock after purchasing an additional 66,382 shares during the period. Knights of Columbus Asset Advisors LLC owned about 0.14% of ARS Pharmaceuticals worth $1,351,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SPRY. Nisa Investment Advisors LLC grew its holdings in shares of ARS Pharmaceuticals by 10.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,281 shares of the company’s stock valued at $110,000 after acquiring an additional 590 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in ARS Pharmaceuticals by 16.1% during the second quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock valued at $98,000 after purchasing an additional 777 shares during the last quarter. Matisse Capital grew its stake in ARS Pharmaceuticals by 1.8% in the second quarter. Matisse Capital now owns 56,714 shares of the company’s stock valued at $990,000 after purchasing an additional 1,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in ARS Pharmaceuticals by 3.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,994 shares of the company’s stock worth $596,000 after purchasing an additional 1,234 shares during the last quarter. Finally, Profund Advisors LLC raised its stake in shares of ARS Pharmaceuticals by 8.0% during the 2nd quarter. Profund Advisors LLC now owns 17,088 shares of the company’s stock worth $298,000 after purchasing an additional 1,264 shares in the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Down 2.3%

SPRY opened at $9.99 on Friday. ARS Pharmaceuticals, Inc. has a twelve month low of $6.66 and a twelve month high of $18.90. The company has a debt-to-equity ratio of 1.14, a quick ratio of 6.51 and a current ratio of 6.66. The business has a 50 day moving average price of $10.58 and a 200 day moving average price of $11.48. The firm has a market cap of $987.51 million, a P/E ratio of -12.33 and a beta of 0.80.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). The firm had revenue of $32.50 million during the quarter, compared to the consensus estimate of $28.87 million. ARS Pharmaceuticals had a negative net margin of 56.06% and a negative return on equity of 38.77%. Research analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

Insider Activity

In other ARS Pharmaceuticals news, insider Justin Chakma sold 166,380 shares of ARS Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $8.87, for a total value of $1,475,790.60. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Brian Dorsey sold 21,828 shares of the stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $8.71, for a total value of $190,121.88. Following the completion of the sale, the chief operating officer directly owned 10,789 shares of the company’s stock, valued at $93,972.19. This represents a 66.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 33.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Roth Mkm started coverage on ARS Pharmaceuticals in a research note on Tuesday, November 4th. They issued a “buy” rating and a $30.00 price target for the company. Zacks Research downgraded shares of ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, ARS Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $33.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.